1. These RnA drugs would be contract manufactured 2. Forget about market penetration as there is no competition in these specific rare disease areas and the cost is paid by government (creating a saving compared to dialysis machines and staffing) Rohan Hockings would have a good handle on this through their association with Lions Eye 3. There is no way someone like Alan Tribe would ever sell out cheaply … he simply doesn’t need the extra money … he will understand the positive global impact on millions of people, the impact on the West Australian economy … and this company in good time will likely make him deservedly the wealthiest person in Australia … 4. The time has come to forget about comparing PYC with Australian companies, if those eye drugs get through the trials, it will definitely be listing in the USA in the foreseeable future 5. We are ignoring drug candidates that PYC will be holding in the safe deposit box ready to unleash once they have a more robust balance sheet and adequate funding for new trials etc.
PYC have 64 scientists working furiously out of the Harry Perkins facility … and they are no longer working on RP 11, ADOA, PKD or PMS. … so what are they working on??
the mind now boggles …
PYC Price at posting:
19.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)